Cantargia AB
Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which… Read more
Cantargia AB (CANTA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.943x
Based on the latest financial reports, Cantargia AB (CANTA) has a cash flow conversion efficiency ratio of 0.943x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr280.72 Million) by net assets (Skr297.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cantargia AB - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Cantargia AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Cantargia AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cantargia AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IGM Biosciences Inc
NASDAQ:IGMS
|
-0.503x |
|
AQUILA ACQ.CORP. CL.A
F:T81
|
N/A |
|
AME Elite Consortium Bhd
KLSE:5293
|
0.099x |
|
Proact IT Group AB (publ)
LSE:0GT3
|
0.086x |
|
Kish Bancorp Inc
OTCQX:KISB
|
0.037x |
|
Veranda Learning Solutions Limited
NSE:VERANDA
|
0.042x |
|
Mahanagar Telephone Nigam Limited
NSE:MTNL
|
0.004x |
|
ÖKOWORLD AG
F:VVV3
|
N/A |
Annual Cash Flow Conversion Efficiency for Cantargia AB (2011–2024)
The table below shows the annual cash flow conversion efficiency of Cantargia AB from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr116.30 Million | Skr-162.75 Million | -1.399x | +17.63% |
| 2023-12-31 | Skr168.74 Million | Skr-286.66 Million | -1.699x | -84.45% |
| 2022-12-31 | Skr389.68 Million | Skr-358.92 Million | -0.921x | -41.63% |
| 2021-12-31 | Skr532.75 Million | Skr-346.44 Million | -0.650x | -270.89% |
| 2020-12-31 | Skr891.93 Million | Skr-156.39 Million | -0.175x | +77.58% |
| 2019-12-31 | Skr142.27 Million | Skr-111.25 Million | -0.782x | -15.81% |
| 2018-12-31 | Skr155.04 Million | Skr-104.69 Million | -0.675x | -304.30% |
| 2017-12-31 | Skr246.12 Million | Skr-41.10 Million | -0.167x | +84.31% |
| 2016-12-31 | Skr37.13 Million | Skr-39.53 Million | -1.065x | +1.35% |
| 2015-12-31 | Skr28.05 Million | Skr-30.28 Million | -1.079x | -164.11% |
| 2014-12-31 | Skr4.10 Million | Skr6.90 Million | 1.683x | +163.81% |
| 2013-12-31 | Skr3.13 Million | Skr-8.26 Million | -2.638x | -114.81% |
| 2012-12-31 | Skr3.08 Million | Skr-3.78 Million | -1.228x | +35.02% |
| 2011-12-31 | Skr1.54 Million | Skr-2.92 Million | -1.890x | -- |